Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Tumori Journal|2019Cited by 6
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Journal of Clinical Medicine|2025Cited by 4
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Luigia Stefania Stucci et al.|Cancers|2025Cited by 3
Biweekly Combination of Trastuzumab, Docetaxel and Gemcitabine for HER2-Positive Metastatic Breast Cancer: Results of a Phase II GOIM StudyLaura Orlando, Francesco Giotta, Vito Lorusso et al.|Future Oncology|2014Cited by 3
BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Preprints.org|2025Cited by 1